Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Table 4 Advances of TRK inhibitors

Drug	Brand name	Manufacturer	Targets	Applications of diseases	Approved years or current phases of clinical trials
Larotrectinib	Vitrakvi	Lilly’s Loxo Oncology Inc	TRK	TRK fusion + solid tumors	2018 [95, 96]
Entrectinib	Rozlytrek	Genentech Inc	TRK, ROS1, ALK	Advanced ROS1 + NSCLC	2019^§ [68, 200]
Entrectinib	Rozlytrek	Genentech Inc	TRK, ROS1, ALK	TRK fusion + solid tumors	2019^§ [200]
Investigational drugs
Selitrectinib (LOXO-195)	-	Lilly’s Loxo Oncology Inc	TRK, most resistant TRK mutations	TRK fusion + solid tumors	I [102]
Repotrectinib (TPX-0005)	-	Turning Point	TRK, ROS1, ALK, most resistant TRK mutations	ROS1, NTRK, or ALK fusion gene fusion solid tumors	[103] I/II (NCT03093116), I/II (NCT04094610)

In the last column of “Approved years or current phases of clinical trials”: larotrectinib was firstly approved by Food and Drug Administration (FDA), entrectinib was firstly approved by Ministry of Health, Labor and Welfare (MHLW), other two drugs are under investigation, we provided current phases of their clinical trials
TRK Tropomyosin receptor kinase, NSCLC non-small cell lung cancer
Data source: www.fda.gov, www.drugs.com, and www.clinicaltrials.gov (cutoff date: 19 July 2020)

ISSN: 1756-8722